[1] [1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.

[2] [2] VISVANATHAN K, FABIAN C J, BANTUG E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO Clinical Practice Guideline Update[J]. J Clin Oncol, 2019, 37 (33): 3152-3165.

[3] [3] BURSTEIN H J, LACCHETTI C, ANDERSON H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline Focused Update[J]. J Clin Oncol, 2019, 37(5): 423-438.

[4] [4] ARCH J J, CRESPI C M, LEVIN M E, et al. Randomized controlled pilot trial of a low-touch remotely-delivered values intervention to promote adherence to adjuvant endocrine therapy among breast cancer survivors[J]. Ann Behav Med, 2022, 56 (8): 856-871.

[5] [5] HERSHMAN D L, KUSHI L H, SHAO T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8 769 early-stage breast cancer patients[J]. J Clin Oncol, 2010, 28(27): 4120-4128.

[6] [6] LAMBERT L K, BALNEAVES L G, HOWARD A F, et al. Understanding adjuvant endocrine therapy persistence in breast cancer survivors[J]. BMC Cancer, 2018, 18(1): 732.

[7] [7] PANTUZZA L L N, NASCIMENTO E, CREPALDE-RIBEIRO K, et al. Medication literacy: a conceptual model[J]. Res Social Adm Pharm, 2022, 18(4): 2675-2682.

[8] [8] ZHENG F, DING S, LAI L, et al. Relationship between medication literacy and medication adherence in inpatients with coronary heart disease in Changsha, China[J]. Front Pharmacol, 2019, 10: 1537.

[10] [10] DON N. Health literacy as a public health goal: a challenge for contemporary health education and communication strategies into the 21st century[J]. Health Promot Int, 2000, 15(3): 259-267.

[11] [11] RAYNOR D K. Addressing medication literacy: a pharmacy practice priority[J]. Int J Pharm Pract, 2010, 17(5): 257-259.

[12] [12] POULIOT A, VAILLANCOURT R, STACEY D, et al. Defining and identifying concepts of medication literacy: an international perspective[J]. Res Social Adm Pharm, 2018, 14(9): 797-804.

[13] [13] MANIACI M J, HECKMAN M G, DAWSON N L. Functional health literacy and understanding of medications at discharge[J]. Mayo Clinic Proceedings, 2008, 83(5): 554-558.

[15] [15] YEH Y C, LIN H W, CHANG E H, et al. Development and validation of a Chinese medication literacy measure[J]. Health Expect, 2017, 20(6): 1296-1301.

[16] [16] SAUCEDA J A, LOYA A M, SIAS J J, et al. Medication literacy in Spanish and English: psychometric evaluation of a new assessment tool[J]. J Am Pharm Assoc, 2012, 52(6): e231-e240.

[18] [18] ZHANG N, WANG L, OUYANG Y Q, et al. Survey on medication information literacy and influencing factors among pregnant Chinese women[J]. J Matern Fetal Neonatal Med, 2021, 34(10): 1619-1626.

[20] [20] PAGAN E, RUGGERI M, BIANCO N, et al. Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer[J]. Breast, 2024, 77: 103765.

[21] [21] BOSCO-LVY P, JOV J, ROBINSON P, et al. Persistence to 5-year hormonal breast cancer therapy: a French national population-based study[J]. Br J Cancer, 2016, 115(8): 912-919.

[22] [22] XU H, JIN F, ZHANG X J, et al. Adherence status to adjuvant endocrine therapy in Chinese women with early breast cancer and its influencing factors: a cross-sectional survey[J]. Cancer Med, 2020, 9(11): 3703-3713.

[23] [23] BERKOWITZ M J, THOMPSON C K, ZIBECCHI L T, et al. How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support[J]. J Cancer Surviv, 2021, 15(1): 29-39.

[24] [24] TOLEDO G, OCHOA C Y, FARIAS A J. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors[J]. Support Care Cancer, 2020, 28 (1): 271-278.

[25] [25] ZHAO R, LIU H, GAO J. Side effects of endocrine therapy are associated with depression and anxiety in breast cancer patients accepting endocrine therapy: a cross-sectional study in China[J]. Front Psychol, 2022, 13: 905459.

[26] [26] TOIVONEN K, WILLIAMSON T, CARLSON L, et al. Potentially modifiable factors associated with adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review[J]. Cancers, 2020, 13(1): 107.

[27] [27] MAUSBACH B T, SCHWAB R B, IRWIN S A. Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and Meta-analysis[J]. Breast Cancer Res Treat, 2015, 152(2): 239-246.

[28] [28] YANG S, PARK S W, BAE S J, et al. Investigation of factors affecting adherence to adjuvant hormone therapy in early-stage breast cancer patients: a comprehensive systematic review[J]. J Breast Cancer, 2023, 26(4): 309-333.

[29] [29] LONG Y, XIE S, LIU Q, et al. The experiences of adjuvant endocrine therapy for women breast cancer survivors: a literature review[J]. Medicine (Baltimore), 2023, 102(51): e36704.

[30] [30] LIU Y, MALIN J L, DIAMANT A L, et al. Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication[J]. Breast Cancer Res Treat, 2013, 137(3): 829-836.

[31] [31] KAFALOVA D. Clinical pharmacist-led interventions for improving breast cancer management—a scoping review[J]. Current Oncology, 2024, 31(8): 4178-4191.

[35] [35] BRIGHT E E, GENUNG S R, STANTON A L, et al. A mixedmethods study of the technical feasibility and patient acceptability of a real-time adherence monitor in breast cancer survivors taking adjuvant endocrine therapy[J]. Breast Cancer Res Treat, 2022, 195(3): 393-399.

[36] [36] STEWART S F, SLODKOWSKA-BARABASZ J, MCGEAGH L, et al. Development of the HT & Me intervention to support women with breast cancer to adhere to adjuvant endocrine therapy and improve quality of life[J]. Breast, 2023, 70: 32-40.

[37] [37] GERNIER F, GRELLARD J M, DUPONT C, et al. Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study[J]. BMC Cancer, 2023, 23(1): 736.

[38] [38] PANGARSA E A, RIZKY D, TANDARTO K, et al. The effect of multidisciplinary team on survival rates of women with breast cancer: a systematic review and Meta-analysis[J]. Ann Med Surg (Lond), 2023, 85(6): 2940-2948.